NCT02703272 2022-12-02
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 3 Terminated
Janssen Research & Development, LLC
Seagen Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seagen Inc.
Dana-Farber Cancer Institute
University of California, San Francisco